Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp

Context Therapeutics (NASDAQ:CNTX) was upgraded by stock analysts at Citizens Jmp to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research note on Monday, September 23rd. JMP Securities began coverage on Context Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $4.00 target price on the stock. Finally, D. Boral Capital initiated coverage on shares of Context Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $9.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $6.33.

Context Therapeutics Stock Performance

NASDAQ CNTX opened at $1.21 on Wednesday. The business’s 50 day moving average price is $1.50 and its 200-day moving average price is $1.93. Context Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $2.75. The company has a market cap of $90.75 million, a P/E ratio of -1.33 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, equities analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its holdings in Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares during the period. Ally Bridge Group NY LLC increased its holdings in shares of Context Therapeutics by 159.8% in the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after acquiring an additional 1,160,281 shares during the period. Great Point Partners LLC bought a new position in shares of Context Therapeutics in the 2nd quarter worth $14,876,000. Affinity Asset Advisors LLC lifted its stake in shares of Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in Context Therapeutics during the second quarter valued at about $10,348,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.